Divi's Laboratories quarterly results

·Pharma & HealthChart ›
Q1 FY27 · Apr–Jun 2026
₹ croreQ1 FY27Q1 FY26Change
Revenue3,0802,410+27.8%
EBITDA1,255729+72.2%
EBITDA margin40.8%30.3%+10.5 pts
Profit before tax1,180733+61.0%
Net profit902545+65.5%
EPS₹33.95₹20.49+65.7%

Every quarter

₹ crore except per share
Tap a line for its trendQ1 FY27Jun 2026Q4 FY26Mar 2026Q3 FY26Dec 2025Q2 FY26Sep 2025Q1 FY26Jun 2025Q4 FY25Mar 2025Q3 FY25Dec 2024Q2 FY25Sep 2024Q1 FY25Jun 2024Q4 FY24Mar 2024Q3 FY24Dec 2023Q2 FY24Sep 2023Earlier quartersAlpha Plus
3,0802,8312,6042,7152,4102,5852,3192,3382,1182,3031,8551,909
Earlier quartersEvery year the company has filed comes with Alpha Plus.
64.015588.014511986.082.010679.079.095.086.0
3,1442,9862,6922,8602,5292,6712,4012,4442,1972,3821,9501,995
Expenses
1,5031,2141,2179371,0109311,021976893898794711
0.00.00.00.00.00.00.00.00.06.00.00.0
−517−95.0−272136−54.050.0−99.0−7.0−40.0−2.0−65.099.0
408381367354340350297304292297268266
6.06.06.08.03.01.00.01.00.02.00.01.0
13312011811311210799.099.097.095.095.095.0
431397402400385368357349351373369354
1,9642,0231,8381,9481,7961,8071,6751,7221,5931,6691,4611,526
1,255934890888729886743716622731489479
1,122814772775617779644617525636394384
Profit
1,180963854912733864726722604713489469
0.00.0−74.00.00.00.00.00.00.00.00.00.0
1,180963780912733864726722604713489469
291249208220191228174218179160122107
−13.0−37.0−11.03.0−3.0−26.0−37.0−6.0−5.015.09.014.0
278212197223188202137212174175131121
902751583689545662589510430538358348
902751583689545662589510430538358348
2.0−1.016.03.03.00.01.01.01.0−7.05.01.0
904750599692548662590511431531363349
902751583689545662589510430538358348
Per share
₹33.95₹28.31₹21.98₹25.97₹20.49₹24.93₹22.20₹19.20₹16.20₹20.25₹13.50₹13.11
₹33.95₹28.31₹21.98₹25.97₹20.49₹24.93₹22.20₹19.20₹16.20₹20.25₹13.50₹13.11
Other comprehensive income — detail
2.0−1.016.03.03.00.0——————
2.0−8.017.00.0−1.0−1.0−1.00.0−1.0−5.01.01.0
1.0−2.04.00.00.00.0——————
——————−1.00.00.0−2.00.00.0
1.07.04.05.04.01.01.02.02.0−4.05.00.0
0.02.01.02.00.00.0——————
——————0.01.00.00.01.00.0
904750599692548662590511431531363349
Per share — as-filed variants
₹33.95₹28.31₹21.98₹25.97₹20.49₹24.93₹22.20₹19.20₹16.20₹20.25₹13.50₹13.11
₹33.95₹28.31₹21.98₹25.97₹20.49₹24.93₹22.20₹19.20₹16.20₹20.25₹13.50₹13.11
Derived — gross profit (revenue − materials − purchases − Δ inventories)
2,0941,7121,6591,6421,4541,6041,3971,3691,2651,4011,1261,099
68.0%60.5%63.7%60.5%60.3%62.1%60.2%58.6%59.7%60.8%60.7%57.6%
Adjusted (ex-exceptional items) — derived
1,180963854912733864726722604713489469
0.00.0−74.00.00.00.00.00.00.00.00.00.0
902751638689545662589510430538358348
₹33.95₹28.31₹24.07₹25.97₹20.49₹24.93₹22.20₹19.20₹16.20₹20.25₹13.50₹13.11
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DIVISLAB₹9,558.50

Divi's Laboratories Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersLAURUSLABSCOHANCEGLANDTORNTPHARMZYDUSLIFEMAXHEALTHDRREDDYCIPLAMcap ₹2.53L Cr
View
In ₹ Crore except Per Share
3 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations1,909.01,855.02,303.02,118.02,338.02,319.02,585.02,410.02,715.02,604.02,831.03,080.0
Other Income86.095.079.079.0106.082.086.0119.0145.088.0155.064.0
Total Income1,995.01,950.02,382.02,197.02,444.02,401.02,671.02,529.02,860.02,692.02,986.03,144.0
Expenses
+ Cost of Materials Consumed711.0794.0898.0893.0976.01,021.0931.01,010.0937.01,217.01,214.01,503.0
+ Purchases of Stock-in-Trade0.00.06.00.00.00.00.00.00.00.00.00.0
+ Changes in Inventories99.0-65.0-2.0-40.0-7.0-99.050.0-54.0136.0-272.0-95.0-517.0
+ Employee Benefit Expense266.0268.0297.0292.0304.0297.0350.0340.0354.0367.0381.0408.0
+ Finance Costs1.00.02.00.01.00.01.03.08.06.06.06.0
+ Depreciation & Amortisation95.095.095.097.099.099.0107.0112.0113.0118.0120.0133.0
+ Other Expenses354.0369.0373.0351.0349.0357.0368.0385.0400.0402.0397.0431.0
Total Expenses1,526.01,461.01,669.01,593.01,722.01,675.01,807.01,796.01,948.01,838.02,023.01,964.0
EBITDA479.0489.0731.0622.0716.0743.0886.0729.0888.0890.0934.01,255.0
EBIT384.0394.0636.0525.0617.0644.0779.0617.0775.0772.0814.01,122.0
Profit
PBT before Exceptional Items469.0489.0713.0604.0722.0726.0864.0733.0912.0854.0963.01,180.0
+ Exceptional Items0.00.00.00.00.00.00.00.00.0-74.00.00.0
Pretax Income469.0489.0713.0604.0722.0726.0864.0733.0912.0780.0963.01,180.0
+ Current Tax107.0122.0160.0179.0218.0174.0228.0191.0220.0208.0249.0291.0
+ Deferred Tax14.09.015.0-5.0-6.0-37.0-26.0-3.03.0-11.0-37.0-13.0
Tax Expense121.0131.0175.0174.0212.0137.0202.0188.0223.0197.0212.0278.0
Net Income348.0358.0538.0430.0510.0589.0662.0545.0689.0583.0751.0902.0
+ Net Income — Continuing Ops348.0358.0538.0430.0510.0589.0662.0545.0689.0583.0751.0902.0
+ Other Comprehensive Income1.05.0-7.01.01.01.00.03.03.016.0-1.02.0
Total Comprehensive Income349.0363.0531.0431.0511.0590.0662.0548.0692.0599.0750.0904.0
Net Income to Common348.0358.0538.0430.0510.0589.0662.0545.0689.0583.0751.0902.0
Per Share
Basic EPS13.1113.5020.2516.2019.2022.2024.9320.4925.9721.9828.3133.95
Diluted EPS13.1113.5020.2516.2019.2022.2024.9320.4925.9721.9828.3133.95
Other Comprehensive Income — detail
+ Other Comprehensive Income——————0.03.03.016.0-1.02.0
+ Items NOT to be Reclassified to P&L1.01.0-5.0-1.00.0-1.0-1.0-1.00.017.0-8.02.0
+ Tax on Items NOT to be Reclassified——————0.00.00.04.0-2.01.0
+ Tax on Items NOT to be Reclassified — alt tag0.00.0-2.00.00.0-1.0——————
+ Items to be Reclassified to P&L0.05.0-4.02.02.01.01.04.05.04.07.01.0
+ Tax on Items to be Reclassified——————0.00.02.01.02.00.0
+ Tax on Items to be Reclassified — alt tag0.01.00.00.01.00.0——————
Comprehensive Income — Owners of Parent349.0363.0531.0431.0511.0590.0662.0548.0692.0599.0750.0904.0
Per Share — as-filed variants
Basic EPS — Continuing Operations13.1113.5020.2516.2019.2022.2024.9320.4925.9721.9828.3133.95
Diluted EPS — Continuing Operations13.1113.5020.2516.2019.2022.2024.9320.4925.9721.9828.3133.95
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,099.01,126.01,401.01,265.01,369.01,397.01,604.01,454.01,642.01,659.01,712.02,094.0
Gross Margin %57.5760.7060.8359.7358.5560.2462.0560.3360.4863.7160.4767.99
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)469.0489.0713.0604.0722.0726.0864.0733.0912.0854.0963.01,180.0
− Exceptional Items (reconciliation)0.00.00.00.00.00.00.00.00.0-74.00.00.0
Net Income Adj (tax-effected)348.0358.0538.0430.0510.0589.0662.0545.0689.0638.3751.0902.0
EPS Adj13.1113.5020.2516.2019.2022.2024.9320.4925.9724.0728.3133.95
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.002.002.00
Paid Up Equity Capital53.053.053.053.053.053.053.053.053.053.053.053.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Divi's Labs Q2 FY27 results date

Divi's Laboratories (NSE: DIVISLAB) will announce its Q2 FY27 results (July–September 2026) on Saturday, 7 November 2026, according to the board-meeting notice it filed on 22 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹902 crore, up 65.5% from ₹545 crore in Q1 FY26 and up 20.1% from ₹751 crore in Q4 FY26. Revenue from operations was ₹3,080 crore, up 27.8% year on year and up 8.8% from the previous quarter.

Board-meeting notice filed
22 October 2026
Q2 FY26 results (a year earlier)
7 November 2025
Q1 FY27 results (the latest)
1 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date
7 November 2026Saturday · notice filed 22 Oct
Q1 FY27 net profit
₹902 Cr+65.5% vs Q1 FY26+20.1% vs Q4 FY26
Q1 FY27 revenue
₹3,080 Cr+27.8% vs Q1 FY26+8.8% vs Q4 FY26
Q1 FY27 operating margin
36.4%+10.8 pts vs Q1 FY26+7.7 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier)
₹689 CrRevenue ₹2,715 Cr
Q1 FY27 EPS (basic)
₹33.95

Questions

When will Divi's Labs announce its Q2 FY27 results?

On 7 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 22 October 2026). Last year it reported Q2 FY26 on 7 November 2025.

What will Divi's Labs' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹689 crore and revenue from operations ₹2,715 crore. The latest quarter, Q1 FY27, had a net profit of ₹902 crore and revenue of ₹3,080 crore.

What were Divi's Labs' Q1 FY27 results?

Consolidated net profit was ₹902 crore, up 65.5% from ₹545 crore in Q1 FY26 and up 20.1% from ₹751 crore in Q4 FY26. Revenue from operations was ₹3,080 crore, up 27.8% year on year and up 8.8% from the previous quarter.

How has Divi's Labs' profit changed over the last four quarters?

Net profit by quarter: ₹689 crore in Q2 FY26, ₹583 crore in Q3 FY26, ₹751 crore in Q4 FY26 and ₹902 crore in Q1 FY27. That is ₹2,925 crore over the four quarters, up 26.8% from ₹2,306 crore in the four quarters before. Revenue from operations: ₹2,715 crore, ₹2,604 crore, ₹2,831 crore and ₹3,080 crore.

What was Divi's Labs' net profit in FY26?

Consolidated net profit was ₹2,568 crore in FY26 (April 2025–March 2026), up 17.2% from ₹2,191 crore in FY25. It was ₹1,600 crore in FY24 and ₹1,823 crore in FY23: up 40.8% over three years, 12.1% a year on average.

What was Divi's Labs' revenue in FY26?

Revenue from operations was ₹10,560 crore in FY26 (April 2025–March 2026), up 12.8% from ₹9,360 crore in FY25. It was ₹7,845 crore in FY24 and ₹7,768 crore in FY23: up 36.0% over three years, 10.8% a year on average.

Where do these Divi's Labs figures come from?

From Divi's Laboratories' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.